Prospective biorepository study to identify adaptive mechanisms of resistance in patients with metastatic castration resistant prostate cancer undergoing 177Lu-PSMA-617 radioligand therapy

Prospective biorepository study to identify adaptive mechanisms of resistance in patients with metastatic castration resistant prostate cancer undergoing 177Lu-PSMA-617 radioligand therapy - LUX

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027105

Enrollment

Registered

2021-11-16

Start date

2021-11-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Patients with mCRPC undergoing 177LU-PSMA-RLT and receiving pre- and post treatment CT-guided tissue biopsy as standard of care. During CT-guided biopsy additional samples and blood will be c

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - metastatic castration resistant prostate cancer - undergoing 177Lu-PSMA-RLT - signed biorepository consent

Exclusion criteria

Exclusion criteria: /

Design outcomes

Primary

Measure	Time frame
Histopathological, moleculabicological and biochemical tissue and blood analyses to identify biomarkers for 177Lu-PSMA-RLT.	—

Countries

Germany

Contacts

Public ContactClaudia Kesch

Universitätsklinikum Essen Klinik und Poliklinik für Urologie, Kinderurologie und Uroonkologie

claudia.kesch@uk-essen.de020172382975

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026